ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022
ADMA Biologics has announced it will report its financial results for Q4 2021 and the full year on March 24, 2022, after U.S. markets close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADMA Biologics has announced it will report its financial results for Q4 2021 and the full year on March 24, 2022, after U.S. markets close. The company, which specializes in plasma-derived biologics for immunodeficient patients, will host a conference call on the same day at 4:30 p.m. ET to discuss these results. ADMA currently markets three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®. It operates an FDA-licensed facility in Boca Raton, FL, and is dedicated to treating and preventing infectious diseases.
Positive
- ADMA manufactures and markets three FDA-approved plasma-derived biologics.
- The company has a dedicated FDA-licensed facility for product manufacture in Boca Raton, Florida.
- ADMA's mission focuses on niche patient populations and immune compromised individuals.
Negative
- None.
Details
News Market Reaction – ADMA
The recorded move for ADMA in the trading session of this news was -8.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., March 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 24, 2022 after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 7180004. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
COMPANY CONTACT:
Skyler Bloom
Senior Director, Business Development & Corporate Strategy | 201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.